| Drug General Information |
| Drug ID |
D0S8AV
|
| Former ID |
DNC007018
|
| Drug Name |
SOPHORAFLAVANONE B
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H20O5
|
| Canonical SMILES |
CC(=CCC1=C(C=C(C2=C1OC(CC2=O)C3=CC=C(C=C3)O)O)O)C
|
| InChI |
1S/C20H20O5/c1-11(2)3-8-14-15(22)9-16(23)19-17(24)10-18(25-20(14)19)12-4-6-13(21)7-5-12/h3-7,9,18,21-23H,8,10H2,1-2H3/t18-/m0/s1
|
| InChIKey |
LPEPZZAVFJPLNZ-SFHVURJKSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Estrogen receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Estrogen receptor beta |
Target Info |
Inhibitor |
[1]
|
| CGMP-specific 3',5'-cyclic phosphodiesterase |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancerhsa04915:Estrogen signaling pathway
|
|
Prolactin signaling pathwayhsa00230:Purine metabolism
|
|
cGMP-PKG signaling pathway
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
Plasma membrane estrogen receptor signaling
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor networker_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
|
Validated nuclear estrogen receptor beta network
|
|
Reactome
|
Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathwayR-HSA-383280:Nuclear Receptor transcription pathwayR-HSA-418457:cGMP effects
|
|
WikiPathways
|
Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Integrated Pancreatic Cancer Pathway
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear ReceptorsWP706:SIDS Susceptibility Pathways
|
|
Ovarian Infertility Genes
|
|
Nuclear Receptors
|
| References |
| REF 1 | J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta. |
|---|
| REF 2 | J Nat Prod. 2008 Sep;71(9):1513-7. Epub 2008 Sep 9.Potent inhibition of human phosphodiesterase-5 by icariin derivatives. |
|---|
